JAK2V617F drives Mcl-1 expression and censitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Guo, Jun ^a   Roberts, Lisa ^a   Chen, Zhui ^a,b   Merta, Philip J ^a   Glaser, Keith B ^a   Shah, O Jameel ^a,c  

^a ABBVIE INC   (United States)

^b Novartis Institutes for Biomedical Research   (China)

^c MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; NAVITOCLAX; PHENYLALANINE; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; VALINE; ANILINE DERIVATIVE; JAK2 PROTEIN, HUMAN; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; GENE FUNCTION; GENE MUTATION; GENETIC TRANSCRIPTION; JANUS KINASE 2 GENE; MCL 1 GENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ACUTE MYELOID LEUKEMIA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANILINE COMPOUNDS; BCL-X PROTEIN; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN KINASE INHIBITORS; SULFONAMIDES;

EID: 84925003449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114363     Document Type: Article

References (34)

1. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15:1923-1931.
2. Hayakawa F, Towatari M, Iida H, Wakao H, Kiyoi H et al (1998) Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol. 101:521-528. PMID: 9633897
3. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V et al. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809-816.
4. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC et al. (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87:1692-1697. PMID: 8634413
5. Lewis RS, Ward AC (2008) Stat5 as a diagnostic marker for leukemia. Expert Rev Mol Diagn. 8:73-82. PMID: 18088232
6. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22.
7. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T et al. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092-1097. PMID: 17488875
8. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414-8 doi: 10.1073/pnas.0811761106 PMID: 19470474
9. Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V et al. (2013) Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 4; 15-35 doi: 10.1177/2040620712461047 PMID: 23610611
10. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399.
11. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47-59. PMID: 18097445
12. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67:782-791. PMID: 17234790
13. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula LA et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979. PMID: 17173063
14. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681. PMID: 15902208
15. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 14:3268-3277. doi: 10.1158/1078-0432.CCR-07-4622 PMID: 18519752
16. Gäbler K, Rolvering C, Kaczor J, Eulenfeld R, Mendez SA et al. (2013) Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. J Cell Mol Med 17:265-76. doi: 10.1111/jcmm.12005 PMID: 23301855
17. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 17:393-403. PMID: 15694340
18. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 8:1348-1358. PMID: 17115033
19. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 35:269-335. PMID: 7041539
20. Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK et al. (2013) Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-Driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports 5: 1047-1059 doi: 10.1016/j.celrep.2013.10.038 PMID: 24268771
21. Vannucchi AM, Bogani C, Bartalucci N, Tozzi L, Martinelli S et al. (2011) Inhibitors of PI3K/ Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon. Blood 118:A3835
22. Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K (2010) Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. BLOOD 115: 2901-09 doi: 10.1182/blood-2009-03-209544 PMID: 20160166
23. Rubert J, Qian Z, Andraos R, Guthy D, Radimerski T (2011) Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. BMC cancer 11:24
24. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421-3428. doi: 10.1158/0008-5472.CAN-07-5836 PMID: 18451170
25. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ (2004) Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A 101:15313-7. PMID: 15486085
26. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760 PMID: 16543145
27. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP et al. (2011) Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol. 5: 93-104 doi: 10.1016/j.molonc.2010.10.003 PMID: 21115411
28. Ko TK, Chuah CTH, Huang JWJ, Ng KP, Ong ST (2014) The Bcl-2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotergat 1: 1-6
29. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:945-954. PMID: 11948098
30. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M et al. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 107:351-362.
31. Puthier D, Bataille R, Amiot M (1999) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras / MAP kinase pathway. Eur J Immunol. 29:3945-3950. PMID: 10602002
32. Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B et al. (2007) Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110:370-374. PMID: 17356133
33. Ilaria RL Jr., Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 271:31704-31710. PMID: 8940193
34. Carlesso N, Frank DA, Griffin JD (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 183:811-820. PMID: 8642285